Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.48 |
| ▸ | TNF | P01375 | 3/20 | 0.48 |
| ▸ | IL1B | P01584 | 3/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31292137 | 0.84 | CRBN (0.46) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL1897413 | 0.80 | CRBN (0.45) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL6180923 | 0.78 | CRBN (0.46) | CRBNDDB1IKZF3 | |
| SCHEMBL27479960 | 0.78 | CRBN (0.46) | CRBNDDB1IKZF3 | |
| SCHEMBL8058860 | 0.76 | CRBN (0.48) | CRBNDDB1IKZF3 | |
| SCHEMBL3965614 | 0.76 | CRBN (0.47) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL10192652 | 0.73 | CRBN (0.53) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL21843690 | 0.73 | CRBN (0.49) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL10192664 | 0.73 | CRBN (0.53) | CRBNDDB1TNFIL1BIKZF3 | |
| SCHEMBL2148301 | 0.71 | CRBN (0.47) | CRBNDDB1TNFIL1BIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2504703-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE RESTORATION OF VITAMIN D SENSITIVITY IN VITAMIN D RESISTANT TUMOR CELLS | Celgene Corporation (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066351-A1 | IMMUNOMODULATORY COMPOUNDS FOR THE RESTORATION OF VITAMIN D SENSITIVITY IN VITAMIN D RESISTANT TUMOR CELLS | CELGENE CORPORATION (US) | 2011-06-03 | — | — | WO | disclosed |
| EP-2235535-A2 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009105256-A2 | METHOD OF TREATING CANCER BY ADMINISTERING AN IMMUNOMODULATORY COMPOUND IN COMBINATION WITH A CD40 ANTIBODY OR CD40 LIGAND | CELGENE CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009075797-A2 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |